News
SHJBF
3.000
NaN%
--
Shanghai Junshi Biosciences Completes RMB0.7 Billion Technology Innovation Bond Issuance
TipRanks · 1d ago
Junshi Biosciences Details Stake Reduction by Key Pre-IPO Shareholder
TipRanks · 3d ago
Junshi Biosciences Discloses Reduction in Major Shareholder’s Equity Stake
TipRanks · 08/10 13:39
Shanghai Junshi Biosciences Reports Completion of Shareholder’s Stake Reduction
TipRanks · 08/10 13:18
J.P. Morgan Remains a Hold on Shanghai Junshi Biosciences Co., Ltd. Class H (1877)
TipRanks · 08/08 00:25
Junshi Biosciences Shareholders Approve H-Share Buyback Mandate
TipRanks · 07/27 11:09
Junshi Biosciences Completes RMB300 Million Technology Innovation Bond Issuance
TipRanks · 07/22 13:08
Junshi Biosciences Wins NMPA Nod to Expand Toripalimab Use in Early-Stage Lung Cancer
TipRanks · 07/21 14:09
Junshi Biosciences Calls EGM to Seek Mandate for H-Share Buyback
TipRanks · 07/08 14:38
Junshi Biosciences Sets H Share Register Closure Ahead of July EGM
TipRanks · 07/08 13:07
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) Gets a Buy from UBS
TipRanks · 07/03 00:25
Junshi Biosciences Licenses Autoimmune Antibody Roconkibart to Fosun Wanbang for Greater China
TipRanks · 07/01 12:08
Junshi Biosciences Details Valuation Basis for Assets in Joint Venture
TipRanks · 06/26 15:14
Shanghai Junshi Biosciences Shareholders Approve All Resolutions at 2025 AGM
TipRanks · 06/26 13:12
Shanghai Junshi Biosciences Restructures Board Roles and Governance Committees
TipRanks · 06/26 13:10
Shanghai Junshi Biosciences reshapes board and committees to bolster governance
TipRanks · 06/26 13:07
Junshi Biosciences Discloses Equity Reduction by Major Shareholder Group
TipRanks · 06/15 13:20
Shanghai Junshi Biosciences Sets Up Connected JV to House Key IP Assets
TipRanks · 06/05 15:11
Shanghai Junshi Biosciences Calls 2025 AGM and Seeks Mandate for RMB 2.5 Billion Debt Issuance
TipRanks · 06/05 15:09
Shanghai Junshi Biosciences Sets H Share Register Closure for 2025 AGM
TipRanks · 06/05 14:44
More
Webull provides a variety of real-time SHJBF stock news. You can receive the latest news about Shanghai Junshi through multiple platforms. This information may help you make smarter investment decisions.
About SHJBF
Shanghai Junshi Biosciences Co Ltd is a China-based company primarily engaged in the discovery, development and commercialisation of innovative drugs. The Company’s products primarily include TUOYI toripalimab, recombinant humanized anti-tumor anti-B-and T-lymphocyte attenuator (BTLA) monoclonal Tifcemalimab, MINDEWEI deuremidevir hydrobromide tablets, JUNMAIKANG adalimumab, JUNSHIDA ongericimab, programmed death-1 (PD-1) monoclonal antibody subcutaneous injection formulation and others. The products are primarily used to treat malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. The Company primarily operates its businesses in the domestic and American markets.